{"component": "definition", "props": {"groups": [{"size": 12, "samples": [{"hash": "ea5MYOCTSDq", "uri": "/contracts/ea5MYOCTSDq#clinical-development-plan", "label": "License Agreement (Zai Lab LTD)", "score": 32.3538672142, "published": true}, {"hash": "dWfJQj0ksEe", "uri": "/contracts/dWfJQj0ksEe#clinical-development-plan", "label": "License Agreement (Zai Lab LTD)", "score": 32.1622176591, "published": true}, {"hash": "cNH8sLpABgu", "uri": "/contracts/cNH8sLpABgu#clinical-development-plan", "label": "License Agreement (Turning Point Therapeutics, Inc.)", "score": 31.6064339493, "published": true}], "snippet_links": [{"key": "section-52", "type": "clause", "offset": [36, 47]}], "snippet": "shall have the meaning set forth in Section 5.2.", "hash": "dd39f2ac9ed9d9e5cab1084d8022452e", "id": 1}, {"size": 8, "samples": [{"hash": "krYZt9uuWy4", "uri": "/contracts/krYZt9uuWy4#clinical-development-plan", "label": "Definitive Master Agreement (Global Clean Energy Holdings, Inc.)", "score": 21.0, "published": true}, {"hash": "ikpa9g0G8V", "uri": "/contracts/ikpa9g0G8V#clinical-development-plan", "label": "Definitive Master Agreement (Global Clean Energy Holdings, Inc.)", "score": 21.0, "published": true}, {"hash": "a7QcaCx6D1U", "uri": "/contracts/a7QcaCx6D1U#clinical-development-plan", "label": "Definitive Master Agreement (Global Clean Energy Holdings, Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [58, 91]}, {"key": "the-conditions-precedent", "type": "clause", "offset": [155, 179]}, {"key": "exhibit-a", "type": "clause", "offset": [202, 211]}, {"key": "subsequent-amendments", "type": "clause", "offset": [283, 304]}], "snippet": "means the outline and any and all amendments thereto made during the term of this Agreement, the initial copy of which has been tendered to MDI as part of the Conditions Precedent is attached hereto as Exhibit A and incorporated herein and made part of this Agreement along with all subsequent amendments.", "hash": "2d88639f8d7bfd3a357cce39ae6ba1fd", "id": 2}, {"size": 6, "samples": [{"hash": "UspYc1o2y4", "uri": "/contracts/UspYc1o2y4#clinical-development-plan", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.7323750856, "published": true}, {"hash": "kMr3tDrJAey", "uri": "/contracts/kMr3tDrJAey#clinical-development-plan", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.6557152635, "published": true}, {"hash": "eBewJuh4R2D", "uri": "/contracts/eBewJuh4R2D#clinical-development-plan", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.5544147844, "published": true}], "snippet_links": [{"key": "section-37", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 3.7.", "hash": "baeb4a031b22b368d3c511f1c5e4a735", "id": 3}, {"size": 4, "samples": [{"hash": "5cQqF2meUdM", "uri": "/contracts/5cQqF2meUdM#clinical-development-plan", "label": "Development, Promotion, Distribution and Supply Agreement", "score": 21.0, "published": true}, {"hash": "bTnqYuI9D1g", "uri": "/contracts/bTnqYuI9D1g#clinical-development-plan", "label": "Development, Promotion, Distribution and Supply Agreement (Bristol Myers Squibb Co)", "score": 18.0, "published": true}, {"hash": "7Uqn8C71oSd", "uri": "/contracts/7Uqn8C71oSd#clinical-development-plan", "label": "Development, Promotion, Distribution and Supply Agreement (Imclone Systems Inc/De)", "score": 18.0, "published": true}], "snippet_links": [{"key": "approved-by", "type": "definition", "offset": [47, 58]}, {"key": "pursuant-to-section", "type": "clause", "offset": [67, 86]}], "snippet": "means the definitive clinical development plan approved by the PDC pursuant to Section 4.3(b), and each subsequent definitive clinical development plan approved by the PDC pursuant to Section 4.3(e).", "hash": "dd61062946634c6fec44f9e2f3f01761", "id": 4}, {"size": 4, "samples": [{"hash": "2Mfyy04pKyX", "uri": "/contracts/2Mfyy04pKyX#clinical-development-plan", "label": "License and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "kG9uaXDfhGC", "uri": "/contracts/kG9uaXDfhGC#clinical-development-plan", "label": "License and Collaboration Agreement (Protagonist Therapeutics, Inc)", "score": 28.5783709788, "published": true}], "snippet_links": [{"key": "the-parties", "type": "clause", "offset": [6, 17]}, {"key": "written-plan", "type": "clause", "offset": [19, 31]}, {"key": "development-of-the", "type": "clause", "offset": [49, 67]}, {"key": "initial-product", "type": "definition", "offset": [68, 83]}, {"key": "development-term", "type": "clause", "offset": [95, 111]}, {"key": "as-amended", "type": "definition", "offset": [113, 123]}, {"key": "from-time-to-time", "type": "clause", "offset": [124, 141]}, {"key": "pursuant-to-section", "type": "clause", "offset": [142, 161]}, {"key": "budget-and-timelines", "type": "clause", "offset": [183, 203]}, {"key": "attached-hereto-as-exhibit", "type": "definition", "offset": [276, 302]}], "snippet": "means the Parties\u2019 written plan for the clinical Development of the Initial Product during the Development Term, as amended from time to time pursuant to Section 3.2.2, including the budget and timelines described in Section 3.2.1(a). The initial Clinical Development Plan is attached hereto as Exhibit A.", "hash": "c6faa9e5eaa0596ceb1d1c10ee700ab5", "id": 5}, {"size": 3, "samples": [{"hash": "bKbVNe5kW6S", "uri": "/contracts/bKbVNe5kW6S#clinical-development-plan", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "7zco0EfkoBW", "uri": "/contracts/7zco0EfkoBW#clinical-development-plan", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5LMGgLA0F2E", "uri": "/contracts/5LMGgLA0F2E#clinical-development-plan", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-32", "type": "clause", "offset": [43, 54]}], "snippet": "shall have the meaning assigned thereto in Section 3.2.", "hash": "2d2c04fedbb50a4563b99f9464265158", "id": 6}, {"size": 3, "samples": [{"hash": "b37V8TSNHvg", "uri": "/contracts/b37V8TSNHvg#clinical-development-plan", "label": "Product Research, Development, License and Commercialization Agreement (Intercept Pharmaceuticals Inc)", "score": 23.7378507871, "published": true}, {"hash": "kJbZuwKctG8", "uri": "/contracts/kJbZuwKctG8#clinical-development-plan", "label": "Product Research, Development, License and Commercialization Agreement (Intercept Pharmaceuticals Inc)", "score": 23.674880219, "published": true}, {"hash": "2nHrGUHYUTu", "uri": "https://www.sec.gov/Archives/edgar/data/1270073/000114420412049445/v321826_ex99-2.htm", "label": "Amendment (Intercept Pharmaceuticals Inc)", "score": 11.674880219, "published": false}], "snippet_links": [{"key": "particular-product", "type": "definition", "offset": [63, 81]}, {"key": "clinical-development-activities", "type": "clause", "offset": [101, 132]}, {"key": "by-the-parties", "type": "clause", "offset": [149, 163]}, {"key": "marketing-authorizations", "type": "definition", "offset": [191, 215]}, {"key": "the-eu", "type": "clause", "offset": [224, 230]}, {"key": "the-united-states-of-america", "type": "clause", "offset": [235, 263]}, {"key": "clinical-development-plans", "type": "clause", "offset": [265, 291]}, {"key": "reviewed-by", "type": "definition", "offset": [292, 303]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [312, 338]}, {"key": "from-time-to-time", "type": "clause", "offset": [413, 430]}], "snippet": "means the JSC-reviewed written clinical development plan for a particular Product, setting forth the clinical development activities to be conducted by the Parties with the goal of achieving Marketing Authorizations in both the EU and the United States of America. Clinical Development Plans reviewed by the JSC pursuant to this Agreement shall be attached to and made a part of this Agreement and may be amended from time to time.", "hash": "6f37a1965f619103b324c3fd330ff79e", "id": 7}, {"size": 3, "samples": [{"hash": "gxKtMpBVXg3", "uri": "/contracts/gxKtMpBVXg3#clinical-development-plan", "label": "Collaboration Agreement (I-Mab)", "score": 31.3244353183, "published": true}, {"hash": "lLwvDxFu7vl", "uri": "/contracts/lLwvDxFu7vl#clinical-development-plan", "label": "Collaboration Agreement (I-Mab)", "score": 30.8234086242, "published": true}, {"hash": "gZ81zqDiZqa", "uri": "/contracts/gZ81zqDiZqa#clinical-development-plan", "label": "Collaboration Agreement (I-Mab)", "score": 30.6755646817, "published": true}], "snippet_links": [{"key": "subject-to-section-3", "type": "clause", "offset": [7, 27]}, {"key": "by-either-party", "type": "clause", "offset": [92, 107]}, {"key": "this-agreement", "type": "clause", "offset": [114, 128]}, {"key": "from-time-to-time", "type": "clause", "offset": [149, 166]}, {"key": "according-to", "type": "definition", "offset": [167, 179]}, {"key": "section-6", "type": "definition", "offset": [180, 189]}], "snippet": "means, subject to Section 3, a plan for the Clinical Development activities to be performed by either Party under this Agreement that may be amended from time to time according to Section 6.", "hash": "7b25a1eaf421946e3913f11565a64be6", "id": 8}, {"size": 3, "samples": [{"hash": "j3aBGuMMuV8", "uri": "/contracts/j3aBGuMMuV8#clinical-development-plan", "label": "Drug License and Development Agreement (Lantern Pharma Inc.)", "score": 31.288843258, "published": true}, {"hash": "6LbQyKTZahX", "uri": "/contracts/6LbQyKTZahX#clinical-development-plan", "label": "Drug License and Development Agreement (Lantern Pharma Inc.)", "score": 31.0616016427, "published": true}], "snippet_links": [], "snippet": "has the meaning set forth in Section 4.2(b).", "hash": "c8e3e6cf30e6eb5db62781c0e70a3313", "id": 9}, {"size": 3, "samples": [{"hash": "9PnLzp6dzA6", "uri": "/contracts/9PnLzp6dzA6#clinical-development-plan", "label": "Licence Agreement", "score": 31.340862423, "published": true}, {"hash": "AiZjOaRZPd", "uri": "https://s28.q4cdn.com/726829854/files/doc_financials/2016/q3/SRRA-(Sierra-Oncology-Inc.)-(10-Q)-2016-11-10.pdf", "label": "s28.q4cdn.com", "score": 10.0198494182, "published": false}], "snippet_links": [{"key": "the-plan", "type": "clause", "offset": [6, 14]}, {"key": "development-of", "type": "clause", "offset": [77, 91]}, {"key": "including-without-limitation", "type": "clause", "offset": [115, 143]}, {"key": "development-activities", "type": "definition", "offset": [170, 192]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [209, 227]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [235, 254]}, {"key": "obtaining-regulatory-approval", "type": "clause", "offset": [255, 284]}, {"key": "licensed-products", "type": "definition", "offset": [289, 306]}, {"key": "in-the-territory", "type": "clause", "offset": [307, 323]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [438, 465]}, {"key": "schedule-9", "type": "definition", "offset": [482, 492]}, {"key": "details-of", "type": "clause", "offset": [573, 583]}, {"key": "progress-report", "type": "definition", "offset": [647, 662]}, {"key": "in-accordance-with", "type": "definition", "offset": [683, 701]}], "snippet": "means the plan which sets forth a detailed overview of the intended clinical development of each Licensed Product, including without limitation a summary of all material development activities to be conducted by or on behalf of ProNAi for the purposes of obtaining Regulatory Approval for Licensed Products in the Territory, together with associated timelines for such activities. An exemplary Clinical Development Plan has been prepared prior to the Effective Date and appended at Schedule 9. The Clinical Development Plan shall be updated at least annually by ProNAi and details of any material updates shall be set forth in the next applicable Progress Report and provided to CPF in accordance with Clause 4.4.1.", "hash": "43bdd8dc854072286ca2817a94117619", "id": 10}], "next_curs": "CmYSYGoVc35sYXdpbnNpZGVyY29udHJhY3RzckILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIiY2xpbmljYWwtZGV2ZWxvcG1lbnQtcGxhbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 96, "title": "Clinical Development Plan", "snippet": "shall have the meaning set forth in Section 5.2.", "id": "clinical-development-plan", "examples": ["The <strong>Clinical Development Plan</strong> shall include (a) an outline of Clinical Trials to be conducted by Zai in the Territory, including the Local Studies and Joint Global Studies; and (b) the material activities to be performed by the Parties to obtain the Regulatory Approvals for the Products in the Territory and to support the Joint Global Studies.", "Changes in the scope or direction of the Development work under this Agreement that would be a material deviation from the <strong>Clinical Development Plan</strong> must be approved by the JSC as set forth in Section 3.2(b); provided that any change with respect to Joint Global Studies shall be consistent with the Joint Global Studies as set forth in the Global Development Plan.", "Each Local Study conducted in the Territory shall be conducted in accordance with the <strong>Clinical Development Plan</strong>, the study protocol approved by any relevant Regulatory Authority, and Applicable Laws in the Territory.", "Once a determination is made by the PDC with respect to the appropriate actions to be taken, the PDC shall review and re-evaluate the relevant <strong>Clinical Development Plan</strong> and the Clinical Budget and make any changes necessary to implement such actions.", "The Steering Committee shall have the authority to generally guide, plan , monitor and, if needed, direct the <strong>Clinical Development Plan</strong>, settle disagreements between the Parties, monitoring the patent filing strategy in the Territory.", "As soon as practicable after the BLA Filing Date, and consistent with the transition plan adopted by the PDC and contained in the initial <strong>Clinical Development Plan</strong>, the Company shall transition such clinical and other studies ongoing with respect to the Products which have been identified in such <strong>Clinical Development Plan</strong> as being transferred to ERS in such transition plan from the Company&#x27;s sole control to the control of the Party(ies) set forth in the initial <strong>Clinical Development Plan</strong>.", "The <strong>Clinical Development Plan</strong> shall contain in reasonable detail the major Development activities and the projected timelines for conducting such activities, including activities designed to achieve Regulatory Approvals for the Products in the Territory.", "Eucodis will keep adequate inventories of Product materials on hand or with suppliers according to the <strong>Clinical Development Plan</strong> and any quantities in inventory which comply with the requirements of the Act.", "Zai shall perform such obligations under the <strong>Clinical Development Plan</strong> in a professional manner, and in compliance in all respects with the <strong>Clinical Development Plan</strong> and the requirements of Applicable Laws, GCP and cGMP.", "Zai shall be primarily responsible for, and shall use Commercially Reasonable Efforts to conduct, all Development activities of the Products in the Field in the Territory in accordance with the <strong>Clinical Development Plan</strong> at Zai\u2019s sole cost subject to Section 5.4(b)."], "related": [["clinical-development", "Clinical Development", "Clinical Development"], ["commercial-development-plan", "Commercial Development Plan", "Commercial Development Plan"], ["initial-development-plan", "Initial Development Plan", "Initial Development Plan"], ["site-development-plan", "site development plan", "site development plan"], ["professional-development-plan", "Professional development plan", "Professional development plan"]], "related_snippets": [], "updated": "2025-07-06T21:58:29+00:00"}, "json": true, "cursor": ""}}